Sydney Jennings

Articles

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

June 09, 2025

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

Beyond the Rash: Collaborative Insights on Pediatric Atopic Dermatitis

June 09, 2025

RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.

Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care

June 09, 2025

RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate to severe atopic dermatitis, underscoring issues in access and clinical inertia.

Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color

June 09, 2025

Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.

Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years

June 09, 2025

RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.

Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis

June 06, 2025

RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.

Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis

June 06, 2025

RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.

Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis

June 06, 2025

RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis

June 06, 2025

RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.

Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study

June 06, 2025

RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.